Recent Updates
Recently added Catalysts
COYA Positive Sentiment

Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS

Wednesday, October 14, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Coya Therapeutics has announced the initiation of an open-label extension for its Phase 2/3 ALSTARS Trial, which evaluates COYA 302 for treating amyotrophic lateral sclerosis (ALS). This decision comes in response to requests from investigators involved in the trial, indicating a positive reception of the ongoing research. The extension aims to further explore the efficacy of COYA 302 in ALS patients.

Market Sentiment Analysis

POSITIVE FACTORS

  • Coya is expanding its clinical trial with an open-label extension.
  • The trial focuses on COYA 302, which targets ALS treatment.
  • The initiative responds to requests from trial investigators.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+10%
120-day peak, hindsight
Typical move
2%
average across 2 past catalysts
Cash runway
~16 mo
Low dilution risk
Lead asset
COYA 302
Phase 2 · Amyotrophic Lateral Sclerosis (ALS)

Full Press Release Details

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced plans to initiate an open-label extension (OLE) of the Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS).Coya plans to initiate the OLE in response to requests from ALSTARS inves

Frequently Asked Questions

What is the ALSTARS Trial?

The ALSTARS Trial evaluates COYA 302 for treating amyotrophic lateral sclerosis (ALS).

What is the purpose of the open-label extension?

The open-label extension aims to further assess the efficacy of COYA 302 in ALS patients.

Why is Coya initiating this extension?

Coya is initiating the extension in response to requests from investigators involved in the trial.

What stage is the ALSTARS Trial currently in?

The ALSTARS Trial is currently in Phase 2/3.

ShareAdd on Google
Tags: COYA Coya Therapeutics COYA 302 ALS Phase 2/3 clinical trial
Last updated: Oct 14, 2026

Biotech snapshot

Cash runway
$43M liquidity · $2M/mo burn
~16 mo
Low dilution risk
Lead asset
COYA 302Phase 2
Amyotrophic Lateral Sclerosis (ALS) →

Catalyst track record

+10%
best trade around COYA's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for COYA.

See every catalyst's timing & PoA →